IXICO has reported results for the 12-months to September 2021. In-line with its recent trading update, revenues were £9.2m while EBITDA was £1.7m, £0.1m ahead of our £1.6m estimate. We see these as strong results in a year impacted by the pandemic and Huntington's Disease (HD) trials de-scopes. The company ended FY21 with a strong order book (£18.8m), cash position of £6.7m and increased net assets of £11.2m. We are leaving our FY22E forecasts unchanged, which, following the announced trial hal ....
07 Dec 2021
Cenkos: IXICO Plc -- FY21 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: IXICO Plc -- FY21 results
IXICO Plc (IXI:LON) | 8.6 0 0.0% | Mkt Cap: 4.17m
- Published:
07 Dec 2021 -
Author:
Chris Donnellan -
Pages:
7
IXICO has reported results for the 12-months to September 2021. In-line with its recent trading update, revenues were £9.2m while EBITDA was £1.7m, £0.1m ahead of our £1.6m estimate. We see these as strong results in a year impacted by the pandemic and Huntington's Disease (HD) trials de-scopes. The company ended FY21 with a strong order book (£18.8m), cash position of £6.7m and increased net assets of £11.2m. We are leaving our FY22E forecasts unchanged, which, following the announced trial hal ....